Fixing the business of healthcare, with HealthStay’s Seán Conaty and Ruairí Tubrid
1 hr 8 min
Some clinics are so overwhelmed by patient enquiries that they switch their phones off for the morning. Meanwhile, nurses are printing referrals, scanning them and manually entering the same information into another system. That’s the problem HealthStay’s Seán Conaty and Ruairí Tubrid are trying to solve, and we sat down on the FWDstart Podcast to discuss how two Irish founders ended up building healthcare software in the UAE. We got into their shift from a consumer medical tourism business to software for hospitals and clinics, what they learned from an early pilot with King’s College Hospital, and why adding an AI chatbot doesn’t help much if the team receiving its enquiries is still working off spreadsheets and personal phones. The conversation also gets into the harder parts of building the company. Seán and Ruairí explain how the regional conflict stalled enterprise contracts and disrupted their hosting, why they stopped taking salaries, and how they rebuilt their infrastructure while raising $1 million over the summer, with existing investors and Enterprise Ireland backing the business. We also discuss selling into an industry some VCs consider too slow, why they price around patient journeys rather than seats or tokens, and what it takes to turn a promising hospital pilot into a paying customer. ----------------------------------------------- 00:00 Intro01:19 Fixing the business of healthcare08:31 From medical tourism marketplace to B2B software15:10 Why patients travel abroad for treatment21:25 Helping hospitals convert enquiries into revenue26:55 Selling to hospitals and navigating long sales cycles29:55 1,000 referrals a month, still using paper33:45 Bringing HealthStay to Ireland35:45 Surviving the conflict and raising $1 million45:17 Building for international markets47:00 Finding a CTO as non-technical founders51:44 Building the software before the AI agents54:35 Pricing AI around patient journeys60:49 The road to $1 million ARR and a Series A63:19 Co-f...